We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A federal court has blocked plans by Mylan Laboratories to launch amlodipine besylate, a generic version of Pfizer’s blockbuster drug Norvasc, during the drug’s pediatric exclusivity period.